Conference on Retroviruses and Opportunistic Infections

Total Page:16

File Type:pdf, Size:1020Kb

Conference on Retroviruses and Opportunistic Infections Program at a Glance 2016 Conference on Retroviruses and Opportunistic Infections February 22-25, 2016 Boston, Massachusetts 2 CROI 2016 General Information CONTENTS General Information General CROI FOUNDATION ..................................................................2 IAS–USA .............................................................................2 CROI 2016 PROGRAM COMMITTEE .................................................3 Scientific Program Committee.......................................................3 Community Liaison Subcommittee ..................................................4 EXTERNAL REVIEWERS..............................................................5 SCHOLARSHIP AWARDEES ..........................................................7 Young Investigators ...............................................................7 International Scholars ............................................................11 Community Educators ............................................................12 CONTINUING MEDICAL EDUCATION ...............................................13 Accreditation Statement ..........................................................13 Objectives.......................................................................13 Statement of Need ...............................................................13 CME Credit Information ...........................................................13 Claiming CME Credits or a Certificate of Participation ..................................13 Disclosure of Financial Relationships ................................................13 Drug and Product Disclaimer.......................................................13 GENERAL INFORMATION . 14 Overview .......................................................................14 Commercial Support...............................................................6 Americans with Disabilities Act.....................................................14 Emergency Services ..............................................................14 Embargo Policies / Social Media ....................................................14 Welcome Reception ..............................................................14 Wi-Fi ...........................................................................14 Meals ..........................................................................14 Overflow Accommodations for Session Rooms........................................15 Website ........................................................................15 Webcasts and Podcasts ...........................................................15 Affiliated Activity Policies..........................................................15 Mobile App......................................................................15 Badges .........................................................................15 Child Care.......................................................................15 Conference Etiquette .............................................................15 CONFERENCE SERVICES ............................................................16 HOTEL INFORMATION ..............................................................17 ABSTRACT PROCESS................................................................19 ORAL SESSIONS.....................................................................21 POSTER SESSIONS, BY CATEGORY..................................................50 DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS ..128 INDEX OF STUDIES RELATED TO WOMEN .........................................134 AUTHOR INDEX ....................................................................137 KEYWORD INDEX ..................................................................165 CONFERENCE SCHEDULE OVERVIEW..................................Inside Back Cover CONVENTION CENTER FLOOR PLANS .......................................Back Cover Printed in USA. © Copyright 2016 IAS–USA/CROI Foundation. All rights reserved. ISBN # 978-0-692-63523-0 CROI 2016 1 General Information CROI FOUNDATION The CROI Foundation is a 501(c)(3) tax-exempt organization in • Has the sole and absolute discretion to veto any policies, the United States that operates exclusively for the charitable and procedures, or actions taken or proposed to be taken by the educational purpose of organizing, promoting, and presenting the CROI PC or the CROI Secretariat that would pose a substantial Conference on Retroviruses and Opportunistic Infections (CROI). risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might Roles and Responsibilities of the CROI Foundation cause the loss of such qualification Volunteer Board of Directors • Oversees the long-term financial and administrative integrity of • Works closely with the CROI Scientific Program Committee (CROI CROI General Information General PC) and IAS-USA to accomplish the mission of CROI • Approves nominations annually for members of the CROI PC and Composition of the CROI Foundation Board of Directors the CROI Chair and Vice Chairs The Board of Directors comprises current and previous CROI Chairs and • Ensures that the CROI PC is responsible for the scientific program Vice Chairs and selected members of the CROI PC. content of CROI • Enters into and oversees the partner agreement with IAS-USA CROI Foundation Board of Directors Constance A. Benson, MD, President Kevin M. De Cock, MD University of California San Diego Centers for Disease Control and Prevention San Diego, CA, United States Nairobi, Kenya John M. Coffin, PhD, Secretary-Treasurer Scott M. Hammer, MD Tufts University Columbia University Medical Center/New York–Presbyterian Hospital Boston, MA, United States New York, NY, United States Elaine J. Abrams, MD John W. Mellors, MD International Center for AIDS Care and Treatment Programs University of Pittsburgh Columbia University Pittsburgh, PA, United States New York, NY, United States Julie M. Overbaugh, PhD Susan P. Buchbinder, MD Fred Hutchinson Cancer Research Center San Francisco Department of Public Health Seattle, WA, United States University of California San Francisco Robert T. Schooley, MD San Francisco, CA, United States University of California San Diego Judith S. Currier, MD, MsC San Diego, CA, United States University of California Los Angeles Richard A. Koup, MD Los Angeles, CA, United States Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, MD, United States IAS–USA The International Antiviral Society–USA is a 501(c)(3) not-for-profit Contact: Executive Director, Donna M. Jacobsen professional education organization. The IAS–USA serves as the Address: 425 California Street, Suite 1450 Conference Secretariat for CROI. San Francisco, CA 94104-2120 The mission of the IAS–USA is to improve the treatment, care, and Phone: 415-544-9400 quality of life for people with HIV, hepatitis C virus, or other viral Website: www.iasusa.org infections through high-quality, relevant, balanced, and needs- oriented education and information for practitioners and scientists who are actively involved in medical care and research. 2 CROI 2016 General Information CROI 2016 SCIENTIFIC PROGRAM COMMITTEE Information General The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The “goodwill ambassadors” of CROI, PC members are also responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, and convening workshops, symposia, and special sessions. Scientific Program Committee Julie M. Overbaugh, PhD Susan P. Buchbinder, MD Judith S. Currier, MD, MSc CROI 2016 Chair CROI 2016 Vice Chair CROI 2016 Vice Chair Fred Hutchinson Cancer San Francisco Department University of California Research Center of Public Health Los Angeles Seattle, WA, University of California Los Angeles, CA, United States San Francisco United States San Francisco, CA, United States Elaine J. Abrams, MD John M. Coffin, PhD Scott M. Hammer, MD ICAP at Columbia University Tufts University Columbia University Medical New York, NY, United States Boston, MA, United States Center New York-Presbyterian Hospital New York, NY, United States Galit Alter, PhD Kevin M. De Cock, MD Diane V. Havlir, MD Ragon Institute of MGH, MIT, Centers for Disease Control University of California and Harvard and Prevention San Francisco Cambridge, MA, United States Nairobi, Kenya San Francisco, CA, United States Constance A. Benson, MD Wafaa M. El-Sadr, Sharon L. Hillier, PhD University of California MD, MPH Magee-Womens Hospital San Diego ICAP at Columbia University of University of Pittsburgh San Diego, CA, United States New York, NY, United States Medical Center Pittsburgh, PA, United States Bruce J. Brew, MD, MBBS Courtney V. Fletcher, James A. Hoxie, MD St. Vincent’s Hospital PharmD University of Pennsylvania Sydney, Australia University of Nebraska Philadelphia, PA, Medical Center United States College of Pharmacy Omaha, NE, United States Ellen G. Chadwick, MD
Recommended publications
  • Monografia Arquivo
    UNIVERSIDADE ESTADUAL DE CAMPINAS FACULDADE DE EDUCAÇÃO FÍSICA Mauricio dos Santos de Oliveira A Evolução da Ginástica Artística Masculina nos Últimos 20 Anos (1987(1987- ---2007)2007) Campinas 2007 Mauricio dos Santos de Oliveira A Evolução da Ginástica Artística Masculina nos Últimos 20 Anos (1987(1987- ---2007)2007) Trabalho de Conclusão de Curso (Graduação) apresentado à Faculdade de Educação Física da Universidade Estadual de Campinas para obtenção do título de Bacharel em Educação Física. Orientador: Marco Antônio Coelho Bortoleto Campinas 2007 Mauricio dos Santos de Oliveira A Evolução da Ginástica Artística Masculina nos Últimos 20 Anos (1987(1987----2007)2007) Este exemplar corresponde à redação final do Trabalho de Conclusão de Curso (Graduação) defendido por Mauricio dos Santos de Oliveira e aprovado pela Comissão julgadora em: 28/11/2007. Marco Antônio Coelho Bortoleto Orientador Laurita Marconi Schiavon Jorge Sergio Pérez Gallardo Vera Aparecida Madruga Forti Campinas 2007 DEDICATÓRIA Dedico este trabalho aos meus pais, Paulo e Ivani, aos meus irmãos, Paulo Francisco e Verônica, e a todos os meus familiares e amigos que de alguma forma me ajudaram ao longo dessa jornada da graduação. Também gostaria de dedicar este trabalho à todas as pessoas que participaram desse processo e que me auxiliaram nos momentos de dificuldade e que também estiveram ao meu lado nos momentos de alegria. AGRADECIMENTOS Gostaria de expressar aqui a minha eterna gratidão a todas as pessoas que direta ou indiretamente fizeram parte do meu caminho ao longo da graduação. Ao meu orientador e amigo Marquinho pela colaboração, disponibilidade, prontidão e apoio ao longo desse processo. A querida Profª Dr.
    [Show full text]
  • UNIVERSITY of CALIFORNIA RIVERSIDE Investigations Into The
    UNIVERSITY OF CALIFORNIA RIVERSIDE Investigations into the Role of TAF1-mediated Phosphorylation in Gene Regulation A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Cell, Molecular and Developmental Biology by Brian James Gadd December 2012 Dissertation Committee: Dr. Xuan Liu, Chairperson Dr. Frank Sauer Dr. Frances M. Sladek Copyright by Brian James Gadd 2012 The Dissertation of Brian James Gadd is approved Committee Chairperson University of California, Riverside Acknowledgments I am thankful to Dr. Liu for her patience and support over the last eight years. I am deeply indebted to my committee members, Dr. Frank Sauer and Dr. Frances Sladek for the insightful comments on my research and this dissertation. Thanks goes out to CMDB, especially Dr. Bachant, Dr. Springer and Kathy Redd for their support. Thanks to all the members of the Liu lab both past and present. A very special thanks to the members of the Sauer lab, including Silvia, Stephane, David, Matt, Stephen, Ninuo, Toby, Josh, Alice, Alex and Flora. You have made all the years here fly by and made them so enjoyable. From the Sladek lab I want to thank Eugene, John, Linh and Karthi. Special thanks go out to all the friends I’ve made over the years here. Chris, Amber, Stephane and David, thank you so much for feeding me, encouraging me and keeping me sane. Thanks to the brothers for all your encouragement and prayers. To any I haven’t mentioned by name, I promise I haven’t forgotten all you’ve done for me during my graduate years.
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]
  • Sr61 Int.Pdf
    1 STATE OF OKLAHOMA 2 2nd Session of the 53rd Legislature (2012) 3 SENATE RESOLUTION 61 By: Holt 4 5 6 AS INTRODUCED 7 A Resolution celebrating the Centennial of Jim Thorpe's gold medal-winning performances in the 1912 8 Olympic Games, Oklahoma's rich Olympic tradition, and the growing Oklahoma Olympic movement and its impact 9 on the 2012 Olympic Games in London. 10 11 12 WHEREAS, Jim Thorpe, a native Oklahoman and American Indian, in 13 1912 represented the United States at the Olympic Games in 14 Stockholm, Sweden. Thorpe won gold medals in the pentathlon and 15 decathlon, and was the first American to win a gold medal in the 16 decathlon, in which he set a world record; and 17 WHEREAS, having been voted numerous times as the greatest 18 athlete of the Twentieth Century, Thorpe is widely regarded as 19 America's greatest all-around male athlete and perhaps the greatest 20 athlete who ever lived; and 21 WHEREAS, in celebration of the Centennial of Jim Thorpe's gold 22 medal-winning performances at the 1912 Olympic Games, the Jim Thorpe 23 Museum and Oklahoma Sports Hall of Fame, home of the Jim Thorpe 24 Req. No. 3462 Page 1 1 Award, is featuring a special exhibit on the 1912 Olympics, 2 featuring artifacts from the 1912 games; and 3 WHEREAS, also in celebration of the Centennial of Jim Thorpe's 4 1912 Olympic performance, the Jim Thorpe Native American Games will 5 be held in Oklahoma City from June 10-17; and 6 WHEREAS, in commemoration of this anniversary of Oklahoma's 7 greatest Olympic achievement, the Oklahoma State Senate wishes to 8 honor Jim Thorpe's performances along with the achievements of the 9 15 Olympians in the Oklahoma Sports Hall of Fame, including John 10 Smith, Shannon Miller, Kenny Monday, J.W.
    [Show full text]
  • 8Th IAS Conference on HIV Pathogenesis, Treatment &
    ONLINE ONLINE OPEN PEER-REVIEWD PEER-REVIEWD ONLINE A PEER-REVIEWD OPEN ACCESS OPEN HIV/AIDS JOURNAL HIV/AIDS JOURNAL CCESS ONLINEONLINE CCESS A OPEN OPEN PEER-REVIEWD ONLINE HIV/AIDS JOURNAL HIV/AIDS HIV/AIDS JOURNAL PEER-REVIEWD PEER-REVIEWD OPEN ACCESSONLINEPEER-REVIEWD A ONLINEPEER-REVIEWD CCESS HIV/AIDS JOURNALPEER-REVIEWD OPEN ACCESS CCESS A OPEN ONLINE ONLINE HIV/AIDS JOURNAL ONLINE PEER-REVIEWDHIV/AIDS JOURNALONLINEONLINE PEER-REVIEWDOPEN ACCESS PEER-REVIEWD ONLINE ONLINE OPEN ACCESSONLINE OPEN HIV/AIDS JOURNAL CCESS OPEN ACCESS HIV/AIDS JOURNAL PEER-REVIEWD PEER-REVIEWD PEER-REVIEWD HIV/AIDS JOURNAL PEER-REVIEWD A HIV/AIDS JOURNAL OPEN ACCESS PEER-REVIEWD PEER-REVIEWD PEER-REVIEWDONLINE HIV/AIDS JOURNAL HIV/AIDS JOURNAL OPEN ACCESS ONLINE ONLINEONLINE HIV/AIDS JOURNAL HIV/AIDS PEER-REVIEWD A PEER-REVIEWD ONLINE ONLINE HIV/AIDS JOURNAL CCESS HIV/AIDS JOURNALOPEN ONLINE PEER-REVIEWDONLINE PEER-REVIEWD HIV/AIDS JOURNAL OPEN PEER-REVIEWDJOURNAL HIV/AIDS HIV/AIDS JOURNAL HIV/AIDS JOURNAL CCESS ONLINE A A ONLINE OPEN ACCESS HIV/AIDS JOURNAL ONLINE HIV/AIDS JOURNAL CCESS PEER-REVIEWD OPEN ACCESS HIV/AIDS JOURNAL OPEN ACCESS ONLINE HIV/AIDS JOURNAL HIV/AIDS ONLINE OPEN OPEN ACCESS HIV/AIDS JOURNAL PEER-REVIEWD OPEN HIV/AIDS JOURNALPEER-REVIEWD PEER-REVIEWD OPEN ACCESS PEER-REVIEWD CCESS A OPEN PEER-REVIEWDONLINE PEER-REVIEWD PEER-REVIEWD HIV/AIDS JOURNALAbstractHIV/AIDS JOURNAL SupplementHIV/AIDS JOURNAL PEER-REVIEWD OPEN ACCESS CCESS PEER-REVIEWD A PEER-REVIEWD A 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention CCESS OPEN ACCESS 19–22 July 2015, Vancouver, Canada OPEN HIV/AIDS JOURNAL Volume 18, Supplement 4 Scan this QR code with your mobile device to view July 2015 the special issue online 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) Journal of the International AIDS Society 2015, 18 (Suppl 4) http://www.jiasociety.org/index.php/jias/article/view/20479 ORAL ABSTRACTS Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice resulted in viral amplification MO Á MONDAY in the mouse.
    [Show full text]
  • Antibody List
    產品編號 產品名稱 PA569955 1110059E24Rik Polyclonal Antibody PA569956 1110059E24Rik Polyclonal Antibody PA570131 1190002N15Rik Polyclonal Antibody 01-1234-42 123count eBeads Counting Beads MA512242 14.3.3 Pan Monoclonal Antibody (CG15) LFMA0074 14-3-3 beta Monoclonal Antibody (60C10) LFPA0077 14-3-3 beta Polyclonal Antibody PA137002 14-3-3 beta Polyclonal Antibody PA14647 14-3-3 beta Polyclonal Antibody PA515477 14-3-3 beta Polyclonal Antibody PA517425 14-3-3 beta Polyclonal Antibody PA522264 14-3-3 beta Polyclonal Antibody PA529689 14-3-3 beta Polyclonal Antibody MA134561 14-3-3 beta/epsilon/zeta Monoclonal Antibody (3C8) MA125492 14-3-3 beta/zeta Monoclonal Antibody (22-IID8B) MA125665 14-3-3 beta/zeta Monoclonal Antibody (4E2) 702477 14-3-3 delta/zeta Antibody (1H9L19), ABfinity Rabbit Monoclonal 711507 14-3-3 delta/zeta Antibody (1HCLC), ABfinity Rabbit Oligoclonal 702241 14-3-3 epsilon Antibody (5H10L5), ABfinity Rabbit Monoclonal 711273 14-3-3 epsilon Antibody (5HCLC), ABfinity Rabbit Oligoclonal PA517104 14-3-3 epsilon Polyclonal Antibody PA528937 14-3-3 epsilon Polyclonal Antibody PA529773 14-3-3 epsilon Polyclonal Antibody PA575298 14-3-3 eta (Lys81) Polyclonal Antibody MA524792 14-3-3 eta Monoclonal Antibody PA528113 14-3-3 eta Polyclonal Antibody PA529774 14-3-3 eta Polyclonal Antibody PA546811 14-3-3 eta Polyclonal Antibody MA116588 14-3-3 gamma Monoclonal Antibody (HS23) MA116587 14-3-3 gamma Monoclonal Antibody (KC21) PA529690 14-3-3 gamma Polyclonal Antibody PA578233 14-3-3 gamma Polyclonal Antibody 510700 14-3-3 Pan Polyclonal
    [Show full text]
  • WO2019226953A1.Pdf
    ) ( 2 (51) International Patent Classification: Street, Brookline, MA 02446 (US). WILSON, Christo¬ C12N 9/22 (2006.01) pher, Gerard; 696 Main Street, Apartment 311, Waltham, MA 0245 1(US). DOMAN, Jordan, Leigh; 25 Avon Street, (21) International Application Number: Somverville, MA 02143 (US). PCT/US20 19/033 848 (74) Agent: HEBERT, Alan, M. et al. ;Wolf, Greenfield, Sacks, (22) International Filing Date: P.C., 600 Atlanitc Avenue, Boston, MA 02210-2206 (US). 23 May 2019 (23.05.2019) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection av ailable) . AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/675,726 23 May 2018 (23.05.2018) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/677,658 29 May 2018 (29.05.2018) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants: THE BROAD INSTITUTE, INC. [US/US]; MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 415 Main Street, Cambridge, MA 02142 (US). PRESI¬ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, DENT AND FELLOWS OF HARVARD COLLEGE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
    [Show full text]
  • STOP HIV/AIDS Backgrounder
    TREATMENT AS PREVENTION STOP HIV/AIDS STOP HIV/AIDS In 2008, the BC-CfE developed a mathematical On February 4, 2010, then-Minister of Health “TREATMENT AS model and a cost-effectiveness evaluation Kevin Falcon announced a four-year $48 million that suggested that the expansion of HAART pilot aimed to evaluate the impact of the HIV PREVENTION” IN coverage would be highly cost-effective, as it Treatment as Prevention strategy in BC. The would prevent AIDS morbidity and mortality. strategy is a pilot project called STOP HIV/AIDS ACTION However, when the impact of the expansion of (Seek and Treat for Optimal Prevention of HIV HAART coverage on HIV transmission was taken and AIDS). Extending HAART via Treatment as into account, the strategy was found to have the The STOP HIV/AIDS pilot aims to expand access Prevention saves lives, prevents potential of becoming cost-averting, as it would to HIV/AIDS treatment and medication among HIV transmission and reduces health costs virtually eliminate vertical transmission of HIV, hard-to-reach and vulnerable populations in and dramatically reduce HIV transmission by all hile an outright cure or a preventive Vancouver’s Downtown Eastside and Prince other routes. Wvaccine for HIV/AIDS remains elusive, George. These regions had been identified as remarkable advances in HIV treatment have Most recently, HPTN 052—a randomized trial of priority sites for the pilot project because they been achieved over the past two decades. HIV sero-discordant (primarily heterosexual) were disproportionately affected by HIV/AIDS. Most significant among these advances is the couples—provided definitive proof of the The pilot project specifically serves individuals development of highly active antiretroviral efficacy of HIV Treatment as Prevention.
    [Show full text]
  • Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Alyssa Lea MacMillan University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Virology Commons Recommended Citation MacMillan, Alyssa Lea, "Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance" (2013). Publicly Accessible Penn Dissertations. 894. https://repository.upenn.edu/edissertations/894 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/894 For more information, please contact [email protected]. Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Abstract APOBEC3 proteins are important for antiretroviral defense in mammals. The activity of these factors has been well characterized in vitro, identifying cytidine deamination as an active source of viral restriction leading to hypermutation of viral DNA synthesized during reverse transcription. These mutations can result in viral lethality via disruption of critical genes, but in some cases is insufficiento t completely obstruct viral replication. This sublethal level of mutagenesis could aid in viral evolution. A cytidine deaminase-independent mechanism of restriction has also been identified, as catalytically inactive proteins are still able to inhibit infection in vitro. Murine retroviruses do not exhibit characteristics of hypermutation by mouse APOBEC3 in vivo. However, human APOBEC3G protein expressed in transgenic mice maintains antiviral restriction and actively deaminates viral genomes. The mechanism by which endogenous APOBEC3 proteins function is unclear. The mouse provides a system amenable to studying the interaction of APOBEC3 and retroviral targets in vivo.
    [Show full text]
  • Supplemental Table S1. Primers for Sybrgreen Quantitative RT-PCR Assays
    Supplemental Table S1. Primers for SYBRGreen quantitative RT-PCR assays. Gene Accession Primer Sequence Length Start Stop Tm GC% GAPDH NM_002046.3 GAPDH F TCCTGTTCGACAGTCAGCCGCA 22 39 60 60.43 59.09 GAPDH R GCGCCCAATACGACCAAATCCGT 23 150 128 60.12 56.52 Exon junction 131/132 (reverse primer) on template NM_002046.3 DNAH6 NM_001370.1 DNAH6 F GGGCCTGGTGCTGCTTTGATGA 22 4690 4711 59.66 59.09% DNAH6 R TAGAGAGCTTTGCCGCTTTGGCG 23 4797 4775 60.06 56.52% Exon junction 4790/4791 (reverse primer) on template NM_001370.1 DNAH7 NM_018897.2 DNAH7 F TGCTGCATGAGCGGGCGATTA 21 9973 9993 59.25 57.14% DNAH7 R AGGAAGCCATGTACAAAGGTTGGCA 25 10073 10049 58.85 48.00% Exon junction 9989/9990 (forward primer) on template NM_018897.2 DNAI1 NM_012144.2 DNAI1 F AACAGATGTGCCTGCAGCTGGG 22 673 694 59.67 59.09 DNAI1 R TCTCGATCCCGGACAGGGTTGT 22 822 801 59.07 59.09 Exon junction 814/815 (reverse primer) on template NM_012144.2 RPGRIP1L NM_015272.2 RPGRIP1L F TCCCAAGGTTTCACAAGAAGGCAGT 25 3118 3142 58.5 48.00% RPGRIP1L R TGCCAAGCTTTGTTCTGCAAGCTGA 25 3238 3214 60.06 48.00% Exon junction 3124/3125 (forward primer) on template NM_015272.2 Supplemental Table S2. Transcripts that differentiate IPF/UIP from controls at 5%FDR Fold- p-value Change Transcript Gene p-value p-value p-value (IPF/UIP (IPF/UIP Cluster ID RefSeq Symbol gene_assignment (Age) (Gender) (Smoking) vs. C) vs. C) NM_001178008 // CBS // cystathionine-beta- 8070632 NM_001178008 CBS synthase // 21q22.3 // 875 /// NM_0000 0.456642 0.314761 0.418564 4.83E-36 -2.23 NM_003013 // SFRP2 // secreted frizzled- 8103254 NM_003013
    [Show full text]
  • Killam Prizes | Prix Killam
    Killam Prizes | Prix Killam Year | Winners | University | Discipline Année Gagnants Université 2021 Michel Bouvier Université de Montréal Health Sciences | sciences de la santé Stephen R. Gill York University Social Sciences | sciences sociales Gilbert Laporte HEC Montréal Engineering | génie Arthur Ripstein University of Toronto Humanities | sciences humaines Douglas Stephan University of Toronto Natural Sciences | sciences de la nature 2020 Cecilia Benoit University of Victoria Social Sciences | sciences sociales Sarah Carter University of Alberta Humanities | sciences humaines Alan Evans Montreal Neurological Institute Health Sciences | sciences de la santé Ted Sargent University of Toronto Engineering | génie Barbara Sherwood Lollar University of Toronto Natural Sciences | sciences de la nature 2019 Yoshua Bengio Université de Montréal Natural Sciences | sciences de la nature André Blais Université de Montréal Social Sciences | sciences sociales Keith W. Hipel University of Waterloo Engineering | génie Stephen W. Scherer University of Toronto Health Sciences | sciences de la santé Lynne Viola University of Toronto Humanities | sciences humaines 2018 André Gaudreault Université de Montréal Humanities | sciences humaines Vladimir Hachinski Western University Health Sciences | sciences de la santé Walter Herzog University of Calgary Engineering | génie James Pinfold University of Alberta Natural Sciences | sciences de la nature Janet Werker University of British Columbia Social Sciences | sciences sociales Canada Council for the Arts
    [Show full text]
  • Shannon Miller
    SHANNON MILLER Shannon Miller remains one of the most decorated gymnasts in history with 7 Olympic medals. (2 gold, 2 silver, 3 bronze) She is the only female athlete to be inducted into the US Olympic Hall of Fame – Twice! (Individual (2006) and Team (2008). Shannon has won an astounding 59 International and 49 National competition medals. Over half of these have been gold. She is the first US gymnast to win 2 World All-Around Titles. Her tally of five medals (2 silver, 3 bronze) at the 1992 Olympics was the most medals won by a US athlete in any sport. At the ’96 Games, she led the “Magnificent Seven” to the US Women’s first ever Team Gold and for the first time for any American gymnast, she captured Gold on the Balance Beam. After retiring from Olympic competition, Shannon received her undergraduate degrees in marketing and entrepreneurship from the University of Houston and her law degree from Boston College. Shannon remains a part of the gymnastics and Olympic communities as an analyst and commentator. In 2010, Shannon launched her company devoted to helping women make their health a priority. She continues to travel the country as a highly sought-after motivational speaker on topics ranging from The Gold Medal Mindset to cancer and survivorship to the importance of health and fitness. In January of 2011, Shannon was diagnosed with a rare form of ovarian cancer. She had the baseball sized tumor removed successfully and followed up with an aggressive chemotherapy regimen. Shannon has remained open and public about her diagnosis and treatment and continues to empower women to make their health a priority.
    [Show full text]